Revenue up 19% but PBT down 25% and the interim dividend has been dropped

What changed

Revenue rose 19.2% to $83.3m, helped by higher accommodation supplement revenue on premium rooms and new funding levels from 1 July 2023. However, reported Underlying EBITDA of $10.5m is below the $11.3m disclosed in HY23 (–7.0%), and both PBT (–25.0% to $1.6m) and NPAT (–17.7% to $1.4m) declined. Operating cash flow jumped to $5.6m from $0.4m, and capex fell to $1.9m from $53.1m in HY23, the prior period having carried a large property purchase. Gross borrowings rose modestly to $97.7m, cash held to $0.9m, and no interim dividend was declared versus 0.70 cps in HY23.

What matters

• Headline EBITDA uplift is a basis-of-comparison story. Management frames "Underlying EBITDA of $10.5m, 50% up on comparative period" against the HY23 pre-NZ IFRS 16 number of $7.0m, while the HY23 reported (post-IFRS 16) figure was $11.3m. On a like-for-like reading, EBITDA is flat-to-down despite 19.2% revenue growth, implying operating leverage went the wrong way.
• PBT is the cleaner read and it fell 25%. The effective tax rate dropped to 13.6% from 21.2%, cushioning NPAT to a 17.7% decline. Using PBT avoids that distortion and makes clear that operating profitability contracted.
• Leverage drifted further. Net debt is about $96.8m and net debt/EBITDA moved to 9.2x from 8.5x. Against that, the omission of the interim dividend (HY23 was 0.70 cps, a 109% payout of HY23 NPAT) looks like a necessary capital-allocation reset rather than a discretionary pause.

Expectations

No numeric EBITDA or revenue guidance range is disclosed in the supplied excerpts; management states only that Underlying EBITDA was at the "upper end of guidance." Annualising HY24 revenue gives $166.6m, about 13.8% above FY23 revenue of $146.3m, consistent with the new funding inflows flowing through second quarter. The FY23 shape was heavily second-half skewed on NPAT (HY23 NPAT of $1.7m flipped to an implied H2 loss of $3.8m on a full-year loss of $2.1m, driven by a property-related item disclosed in the FY23 narrative), so repeating HY24's modest NPAT into the full year is not supported by recent history. The release does not re-commit to any dividend framework or a forward EBITDA target.

Quality of result

The profit line is of mixed quality. Revenue growth is clearly underpinned by recurring funding and price changes rather than one-offs, but operating costs appear to have absorbed most of that uplift — EBITDA did not expand on a consistent basis. The NPAT decline is smaller than the PBT decline only because of a lower effective tax rate, which is not an operating driver. Working capital moved favourably (debtor days to 30.1 from 37.1), contributing to the $5.6m operating cash inflow; OCF/EBITDA of 53.3% is ordinary rather than exceptional, and the very low comparator (0.4m) exaggerates the headline cash-flow jump. The $51m year-on-year swing in capex reflects the absence of a prior-period property acquisition, not a structurally lower investment run-rate.

Unresolved

• A full statutory-to-Underlying EBITDA bridge is not provided in the supplied excerpts, leaving the true like-for-like operating trajectory ambiguous.
• Whether the dividend has been formally suspended, deferred, or re-based is not stated.
• Covenant headroom at 9.2x net debt/EBITDA, and the maturity profile of the $23.0m current bank loans plus $10.5m vendor loan, is not addressed.
• The cost drivers that prevented 19.2% revenue growth from translating into EBITDA growth (wage inflation, occupancy, mix) are not quantified.
• No forward-work or bed-pipeline metric is disclosed.

This briefing cannot assess valuation, covenant compliance, or management's unstated plans for the interim dividend, as none of those are in the supplied materials.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.